α-Adrenoceptor modulation hypothesis of antipsychotic atypicality

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 7, 2003, Pages 1145-1158

  Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic drugs; Clozapine; Dopaminergic dysregulation; Schizophrenia; Stabilization; 1 and 2 Adrenoceptor blockage

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA 2 ADRENERGIC RECEPTOR; AMPEROZIDE; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FENFLURAMINE; HALOPERIDOL; IDAZOXAN; NEUROLEPTIC AGENT; OLANZAPINE; PRAZOSIN; QUETIAPINE; RACLOPRIDE; REBOXETINE; RECEPTOR SUBTYPE; RISPERIDONE; RITANSERIN;

ARTICLE; BRAIN DYSFUNCTION; CLINICAL TRIAL; DEMENTIA; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTATION; HUMAN; MESENCEPHALON; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PREFRONTAL CORTEX; RECEPTOR AFFINITY; SCHIZOPHRENIA;

EID: 0344395561     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.09.009     Document Type: Article

References (167)

1. Andersson J.L., Marcus M., Nomikos G.G., Svensson T.H. Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn Schmiedebergs Arch. Pharmacol. 349:1994;236-243.
2. Angrist B.M., Shopsin B., Gershon S. Comparative psychomimetic effects of stereoisomers of amphetamine. Nature. 234:1971;152-153.
3. Angrist B.M., Sathananthan G., Wilk S., Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatr. Res. 11:1974;13-23.
4. Angrist B., Peselow E., Rubinstein M., Corwin J., Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl.). 78:1982;128-130.
5. Arborelius L., Nomikos G.G., Hacksell U., Svensson T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand. 148:1993;465-466.
6. Arnsten A.F., Cai J.X., Murphy B.L., Goldman-Rakic P.S. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl.). 116:1994;143-151.
7. Ashby C.R. Jr., Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse. 24:1996;349-394.
8. Bakshi V.P., Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J. Pharmacol. Exp. Ther. 283:1997;666-674.
9. Bean A.J., Roth R.H. Extracellular dopamine and neurotensin in rat prefrontal cortex in vivo: effects of median forebrain bundle stimulation frequency, stimulation pattern, and dopamine autoreceptors. J. Neurosci. 11:1991;2694-2702.
10. Blanc G., Trovero F., Vezina P., Herve D., Godeheu A.M., Glowinski J., Tassin J.P. Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical D-amphetamine injection. Eur. J. Neurosci. 6:1994;293-298.
11. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry. 47:1990;181-188.
12. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr. Res. 14:1995;187-202.
13. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2569-2574.
14. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 205:1979;929-932.
15. Bunney B.S., Aghajanian G.K. D-Amphetamine-induced depression of central dopamine neurons: evidence for mediation by both autoreceptors and a striato-nigral feedback pathway. Naunyn Schmiedebergs Arch. Pharmacol. 304:1978;255-261.
16. Bunney B.S., Walters J.R., Roth R.H., Aghajanian G.K. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J. Pharmacol. Exp. Ther. 185:1973;560-571.
17. Bunney B.S., Walters J.R., Kuhar M.J., Roth R.H., Aghajanian G.K. D and L Amphetamine stereoisomers: comparative potencies in affecting the firing of central dopaminergic and noradrenergic neurons. Psychopharmacol. Commun. 1:1975;177-190.
18. Carasso B.S., Bakshi V.P., Geyer M.A. Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats. Neuropharmacology. 37:1998;401-404.
19. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55:1990;1067-1070.
20. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry. 135:1978;165-173.
21. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
22. Carlsson M.L. Experimental hypoglutamatergia model for cognitive deficits of schizophrenia: effects of classical neuroleptics, 5-HT2A receptor blocking antipsychotics, the ampakine CX516 and the dopaminergic stabilizer ACR16. Eur. Neuropsychopharmacol. 12:2002;S167-S168.
23. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989;221-226.
24. Castner S.A., Williams G.V., Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 287:2000;2020-2022.
25. Charlety P.J., Grenhoff J., Chergui K., De la Chapelle B., Buda M., Svensson T.H., Chouvet G. Burst firing of mesencephalic dopamine neurons is inhibited by somatodendritic application of kynurenate. Acta Physiol. Scand. 142:1991;105-112.
26. Chergui K., Charlety P.J., Akaoka H., Saunier C.F., Brunet J.L., Buda M., Svensson T.H., Chovet G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur. J. Neurosci. 5:1993;137-144.
27. Chergui K., Nomikos G.G., Mathe J.M., Gonon F., Svensson T.H. Burst stimulation of the medial forebrain bundle selectively increase Fos-like immunoreactivity in the limbic forebrain of the rat. Neuroscience. 72:1996;141-156.
28. Chergui K., Svenningsson P., Nomikos G.G., Gonon F., Fredholm B.B., Svensson T.H. Increased expression of NGFI-A mRNA in the rat striatum following burst stimulation of the medial forebrain bundle. Eur. J. Neurosci. 9:1997;2370-2382.
29. Clineschmidt B.V., Martin G.E., Bunting P.R., Papp N.L. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res. 2:1982;135-145.
30. Cohen B.M., Lipinski J.F. In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. Life Sci. 39:1986;2571-2580.
31. Coull J.T., Sahakian B.J., Hodges J.R. The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacology (Berl.). 123:1996;239-249.
32. Criswell H.E., Johnson K.B., Mueller R.A., Breese G.R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther. 265:1993;1001-1010.
33. Darracq L., Blanc G., Glowinski J., Tassin J.P. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J. Neurosci. 18:1998;2729-2739.
34. Dean B., Hayes W., Opeskin K., Naylor L., Pavey G., Hill C., Keks N., Copolov D.L. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 73:1996;169-175.
35. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J. Neural Transm. Gen. Sect. 91:1993;197-221.
36. Dickinson S.L., Gadie B., Tulloch I.F. Alpha 1- and alpha 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by D-amphetamine and apomorphine in the rat. Psychopharmacology (Berl.). 96:1988;521-527.
37. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98:2001;6917-6922.
38. Erhardt S., Mathe J.M., Chergui K., Engberg G., Svensson T.H. GABA(B) receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 365:2002;173-180.
39. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry. 45:1988;71-76.
40. Ferré S., Artigas F. Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci. Lett. 187:1995;61-64.
41. Fessler R.G., Sturgeon R.D., Meltzer H.Y. Effects of phencyclidine and methylphenidate on D-amphetamine-induced behaviors in reserpine pretreated rats. Pharmacol. Biochem. Behav. 13:1980;835-842.
42. Freeman A.S., Bunney B.S. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur. J. Pharmacol. 104:1984;287-293.
43. Gariano R.F., Groves P.M. Burst firing induced in midbrain dopamine neurons by stimulation of the medial prefrontal and anterior cingulate cortices. Brain Res. 462:1988;194-198.
44. Goff D.C., Midha K.K., Sarid-Segal O., Hubbard J.W., Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology. 117:1995;417-423.
45. Goldman M.B., Janacek H.M. Adjunctive fluoxetine improves global function in chronic schizophrenia. J. Neuropsychiat. Clin. Neurosci. 2:1990;429-431.
46. Gonon F.G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience. 24:1988;19-28.
47. Grace A.A., Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons: 1. Identification and characterization. Neuroscience. 10:1983;301-315.
48. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry. 153:1996;321-330.
49. Grenhoff J., Svensson T.H. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur. J. Pharmacol. 165:1989;11-18.
50. Grenhoff J., Svensson T.H. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur. J. Pharmacol. 233:1993;79-84.
51. Grenhoff J., Tung C.S., Svensson T.H. The excitatory amino acid antagonist kynurenate induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol. Scand. 134:1988;567-568.
52. Grenhoff J., Nisell M., Ferre S., Aston-Jones G., Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. Neural Transm. Gen .Sect. 93:1993;11-25.
53. Gresch P.J., Sved A.F., Zigmond M.J., Finlay J.M. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem. 65:1995;111-116.
54. Harvey P.D., Howanitz E., Parrella M., White L., Davidson M., Mohs R.C., Hoblyn J., Davis K.L. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am. J. Psychiatry. 155:1998;1080-1086.
55. 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J. Pharmacol. Exp. Ther. 194:1975;47-56.
56. Hertel P., Nomikos G.G., Schilstrom B., Arborelius L., Svensson T.H. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology. 17:1997;44-55.
57. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science. 286:1999;105-107.
58. Hertel P., Nomikos G.G., Svensson T.H. Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur. J. Pharmacol. 371:1999;153-158.
59. Hertel P., Nomikos G.G., Svensson T.H. The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. Neuropharmacology. 38:1999;1175-1184.
60. Hoffman R.E., McGlashan T.H. Parallel distributed processing and the emergence of schizophrenic symptoms. Schizophr. Bull. 19:1993;119-140.
61. Hommer D.W., Zahn T.P., Pickar D., van Kammen D.P. Prazosin, a specific alpha 1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients. Psychiatry Res. 11:1984;193-204.
62. Ichikawa J., Meltzer H.Y. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J. Pharmacol. Exp. Ther. 291:1999;1227-1232.
63. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351:1998;163-171.
64. Ingvar D. Evidence for frontal/prefrontal cortical dysfunction in chronic schizophrenia: the phenomenon of "hypofrontality" reconsidered. Helmchen H., Henn F.A. Biological Perspectives of Schizophrenia. 1987;201-211 Wiley, Chichester.
65. Iyer R.N., Bradberry C.W. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J. Pharmacol. Exp. Ther. 277:1996;40-47.
66. Janowski D., Davis J.M. Methylphenidate dextroamphetamine and levoamphetamine. Arch. Gen. Psychiatry. 33:1976;304-308.
67. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
68. Jentsch J.D., Redmond D.E. Jr., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
69. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1992;336-351.
70. Karoum F., Karson C.N., Bigelow L.B., Lawson W.B., Wyatt R.J. Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch. Gen. Psychiatry. 44:1987;604-607.
71. Kokkinidis L., Anisman H. Involvement of norepinephrine in startle arousal after acute and chronic D-amphetamine administration. Psychopharmacology. 59:1978;285-292.
72. Kokkinidis L., Anisman H. Circling behavior following systemic D-amphetamine administration: potential noradrenergic and dopaminergic involvement. Psychopharmacology (Berl.). 64:1979;45-54.
73. Kolachana B.S., Saunders R.C., Weinberger D.R. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience. 69:1995;859-868.
74. Kornhuber H.H. Chemistry, physiology and neuropsychology of schizophrenia: towards an earlier diagnosis of schizophrenia I. Arch. Psychiatr. Nervenkr. 233:1983;415-422.
75. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
76. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
77. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A post-mortem study. Arch. Gen. Psychiatry. 50:1993;810-818.
78. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seigyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93:1996;9235-9240.
79. Lidow M.S., Williams G.V., Goldman-Rakic P.S. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol. Sci. 19:1998;136-140.
80. Linnér L., Endersz H., Ohman D., Bengtsson F., Schalling M., Svensson T.H. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J. Pharmacol. Exp. Ther. 297:2001;540-546.
81. 2-blockage-unduced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 27:2002;691-698.
82. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry. 168:1996;571-579.
83. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug-sernyl AMA. Arch. Neurol. Psychiatry. 81:1959;363.
84. Lucas G., Bonhomme N., De Deurwaerdere P., Le Moal M., Spampinato U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology. 131:1997;57-63.
85. Maas J.W., Contreras S.A., Miller A.L., Berman N., Bowden C.L., Javors M.A., Seleshi E., Weintraub S. Studies of catecholamine metabolism in schizophrenia/psychosis: I. Neuropsychopharmacology. 8:1993;97-109.
86. Marcus M.M., Nomikos G.G., Svensson T.H. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur. Neuropsychopharmacol. 6:1996;29-38.
87. Marcus M.M., Nomikos G.G., Svensson T.H. Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur. Neuropsychopharmacol. 10:2000;245-253.
88. Marcus M.M., Malmerfelt A., Nyberg S., Svensson T.H. Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses. Eur. Neuropsychopharmacol. 12:2002;379-386.
89. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309:1996;1-11.
90. Mathe J.M., Nomikos G.G., Schilstrom B., Svensson T.H. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J. Neurosci. Res. 51:1998;583-592.
91. Mathe J.M., Nomikos G.G., Blakeman K.H., Svensson T.H. Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology. 38:1999;121-128.
92. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3:1995;64-75.
93. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. International Suicide Prevention Trial St Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry. 60:2003;82-91.
94. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5:2002;267-271.
95. Millan M.J., Schreiber R., Dekeyne A., Rivet J.M., Bervoets K., Mavridis M., Sebban C., Maurel-Remy S., Newman-Tancredi A., Spedding M., Muller O., Lavielle G., Brocco M.S. 16924 ((R)-2-(1-(2-(2,3-dihydro-benzo (1,4) dioxin-5-yloxy)-ethyl)-pyrrolidin-3yl)-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1998;356-1373.
96. Miller D.W., Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res. Bull. 40:1996;57-62.
97. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760.
98. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
99. Murase S., Grenhoff J., Chouvet G., Gonon F.G., Svensson T.H. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci. Lett. 157:1993;53-56.
100. Murase S., Mathe J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J. Neural Transm. Gen. Sect. 91:1993;13-25.
101. Murphy B.L., Arnsten A.F., Jentsch J.D., Roth R.H. Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment. J. Neurosci. 16:1996;7768-7775.
102. Narayanan S., Willins D., Dalia A., Wallace L., Uretsky N. Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol. Biochem. Behav. 54:1996;565-573.
103. Nauta W.J.H. Behavioral alterations in patients with basal ganglia lesions. Yahr M.D. The Basal Ganglia. 1976;177-180 Raven Press, New York.
104. Nomikos G.G., Iurlo M., Andersson J.L., Kimura K., Svensson T.H. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl.). 115:1994;147-156.
105. Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry. 152:1995;1444-1449.
106. Nutt D.J. Putting the "A" in atypical: does alpha2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J. Psychopharmacol. 8:1994;193-195.
107. Ohuoha D.C., Hyde T.M., Kleinman J.E. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology. 112:1993;15-85.
108. Ouagazzal A., Nieoullon A., Amalric M. Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum. Eur. J. Pharmacol. 251:1994;229-236.
109. Pawlowski L., Mathe J.M., Svensson T.H. Phencyclidine activates rat A10 dopamine neurons but reduces burst activity and causes regularization of firing. Acta Physiol. Scand. 139:1990;529-530.
110. Peroutka S.J., Snyder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry. 137:1980;1518-1522.
111. Pickar D., Roy A., Breier A., Doran A., Wolkowitz O., Colison J., Agren H. Suicide and aggression in schizophrenia. Neurobiologic correlates. Ann. N. Y. Acad. Sci. 487:1986;189-196.
112. Potkin S.G., Alva G., Fleming K., Anand R., Keator D., Carreon D., Doo M., Jin Y., Wu J.C., Fallon J.H. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am. J. Psychiatry. 159:2002;227-237.
113. Prinssen E.P., Kleven M.S., Koek W. Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology. 128:1996;191-197.
114. Pycock C.J., Carter C.J., Kerwin R.W. Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J. Neurochem. 34:1980;91-99.
115. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 286:1980;74-76.
116. Raedler T.J., Jahn H., Arlt J., Kiefer F., Schick M., Wiedemann K., Naber D. Adjunctive use of reboxetine in schizophrenia. Schizophr. Res. 53:2002;203.
117. Redgrave P., Prescott T.J., Gurney K. Is the short-latency dopamine response too short to signal reward error? Trends Neurosci. 22:1999;146-151.
118. Rollema H., Lu Y., Schmidt A.W., Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by HT1A receptor activation. Eur. J. Pharmacol. 338:1997;R3-R5.
119. Salmi P., Ahlenius S. Further evidence for clozapine as a dopamine D1 receptor agonist. Eur. J. Pharmacol. 307:1996;27-31.
120. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 71:1994;515-528.
121. Sawaguchi T., Matsumura M., Kubota K. Dopamine enhances the neuronal activity of spatial short-term memory task in the primate prefrontal cortex. Neurosci. Res. 5:1988;465-473.
122. Sawaguchi T., Matsumura M., Kubota K. Effects of dopamine antagonists on neuronal activity related to a delayed response task in monkey prefrontal cortex. J. Neurophysiol. 63:1990;1401-1412.
123. Schmidt C.J., Fadayel G.M. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
124. Schneider J.S., Sun Z.Q., Roeltgen D.P. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res. 663:1994;140-144.
125. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr. Opin. Neurobiol. 7:1997;191-197.
126. Schultz W. Predictive reward signal of dopamine neurons. J. Neurophysiol. 80:1998;1-27.
127. Schutz G., Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int. Clin. Psychopharmacol. 16:2001;275-278.
128. Schultz W., Apicella P., Ljungberg T. Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. J. Neurosci. 13:1993;900-913.
129. Schultz W., Dayan P., Montague P.R. A neural substrate of prediction and reward. Science. 275:1997;1593-1599.
130. Schultz W., Tremblay L., Hollerman J.R. Reward prediction in primate basal ganglia and frontal cortex. Neuropharmacology. 37:1998;421-429.
131. Servan-Schreiber D., Printz H., Cohen J.D. A network model of catecholamine effects: gain, signal-to-noise ratio, and behavior. Science. 249:1990;892-895.
132. Sharma R.P., Shapiro L.E., Kamath S.K., Soll E.A., Watanabe M.D., Davis J.M. Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiology. 35:1997;5-10.
133. Shi W.-X., Pun C.-L., Zhang X.-X., Jones M.D., Bunney B.S. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J. Neurosci. 20:2000;3504-3511.
134. Silver H., Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol. Psychiatry. 31:1992;98-704.
135. Silver H., Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J. Clin. Psychopharmacol. 18:1998;208-211.
136. Soper H.V., Elliott R.O. Jr., Rejzer A.A., Marshall B.D. Jr. Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenic patients. J. Clin. Psychopharmacol. 10:1990;168-175.
137. Spina E., De Domenico P., Ruello C., Longobardo N., Gitto C., Ancione M., Di Rosa A.E., Caputi A.P. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int. Clin. Psychopharmacol. 9:1994;281-285.
138. Svensson T.H. The effect of inhibition of catecholamine synthesis on dexamphetamine induced central stimulation. Eur. J. Pharmacol. 12:1970;161-166.
139. Svensson T.H. Functional and biochemical effects of D- and L-amphetamine on central catecholamine neurons. Naunyn Schmiedebergs Arch. Pharmacol. 271:1971;170-180.
140. Svensson T.H. Brain noradrenaline and the mechanisms of action of antidepressant drugs. Acta Psychiatr. Scand. Suppl. 402:2000;18-27.
141. Svensson T.H., Tung C.S. Local cooling of pre-frontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol. Scand. 136:1989;135-136.
142. Svensson T.H., Mathe J.M., Andersson J.L., Nomikos G.G., Hildebrand B.E., Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. corrected J. Clin. Psychopharmacol. 15(Suppl. 1):1995;115-185.
143. Svensson T.H., Mathe J.M., Nomikos G.G., Schilstrom B., Marcus M., Fagerquist M. Interactions between catecholamines and serotonin: relevance to the pharmacology of schizophrenia. Adv. Pharmacol. 42:1998;814-818.
144. Swanson L.W. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res. Bull. 9:1982;321-353.
145. Taber M.T., Das S., Fibiger H.C. Cortical regulation of subcortical dopamine release: mediation via the ventral tegmental area. J. Neurochem. 65:1995;1407-1410.
146. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology. 115:1994;285-288.
147. Tong Z.Y., Overton P.G., Clark D. Antagonism of NMDA receptors but not AMPA/kainate receptors blocks bursting in dopaminergic neurons induced by electrical stimulation of the prefrontal cortex. J. Neural Transm. 103:1996;889-904.
148. Tong Z.Y., Overton P.G., Clark D. Stimulation of the prefrontal cortex in the rat induces patterns of activity in midbrain dopaminergic neurons which resemble natural burst events. Synapse. 22:1996;195-208.
149. van Kammen D.P., Boronow J.J. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int. Clin. Psychopharmacol. 3:1988;111-121.
150. van Kammen D.P., Kelley M. Dopamine and norepinephrine activity in schizophrenia. An integrative perspective. Schizophr. Res. 4:1991;173-191.
151. van Kammen D.P., Agren H., Yao J.K., O'Connor D.T., Gurklis J., Peters J.L. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am. J. Psychiatry. 151:1994;379-384.
152. Verma A., Moghaddam B. The role of excitatory amino acids in prefrontal cortex function assessed by spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16:1996;373-379.
153. Volkow N.D., Hitzemann R., Wang G.J., Fowler J.S., Wolf A.P., Dewey S.I., Handlesman L. Long-term frontal brain metabolic changes in cocaine abusers. Synapse. 11:1992;184-190.
154. Wadenberg M.L. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev. 20:1996;325-339.
155. Wadenberg M.L., Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J. Neural Transm. 83:1991;43-53.
156. Wadenberg M.L., Salmi P., Jimenez P., Svensson T., Ahlenius S. Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. Eur. Neuropsychopharmacol. 6:1996;305-310.
157. Wadenberg M.L., Hertel P., Fernholm R., Hygge Blakeman K., Ahlenius S., Svensson T.H. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J. Neural Transm. 107:2000;1229-1238.
158. Wang R.Y. Dopaminergic neurons in the rat ventral tegmental area: III. Effects of D- and L-amphetamine. Brain Res. Rev. 3:1981;153-165.
159. Wedzony K., Klimek V., Golembiowska K. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res. 622:1993;325-329.
160. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci. 11:1988;367-370.
161. Weinberger D.R., Berman K.F. Prefrontal function in schizophrenia: confounds and controversies. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351:1996;1495-1503.
162. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry. 45:1988;609-615.
163. Westerink B.H., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikstrom H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 412:2001;127-138.
164. Willins D.L., Narayanan S., Wallace L.J., Uretsky N.J. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol. Biochem. Behav. 46:1993;881-887.
165. Wolf M.E., White F.J., Hu X.T. Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav. Pharmacol. 4:1993;429-442.
166. Wu J.C., Buchsbaum M.S., Bunney W.E. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Yakubutsu Seishin Kodo. 11:1991;47-48.
167. Yamamoto B.K., Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J. Neurochem. 71:1998;274-280.